vioxx gastrointestinal outcomes research
3、心肌梗死： （1）环氧化酶-2抑制剂： 万络胃肠道预后研究（Vioxx Gastrointestinal Outcomes Research，VIGOR）显示，与萘普生（naproxen）相比，选择性环氧化酶-2（COX-2）抑制剂罗非昔布（rofeco...
基于4个网页-相关网页
...和卒中 选择性COX-2抑制剂和心肌梗死危险性增加相 关 万络的胃肠道安全性研究(vioxx gastrointestinal outcomes research,VIGOR）：发现罗非昔布组的 心肌梗死发生率为0.4% ,而用萘普生作为对照组的心 肌梗死发生率为0.1 % ...
基于2个网页-相关网页
vioxx gastrointestinal outcomes research
万络胃肠道结果研究
以上为机器翻译结果，长、整句建议使用 人工翻译 。
-
In that study, researchers looked at the data from two already completed studies, the Vioxx Gastrointestinal Outcomes Research study (VIGOR) and Celecoxib Long-Term Arthritis Safety Study (CLASS), and concluded that both drugs might slightly increase the risk of cardiac events such as heart attack and stroke.
FORBES: Magazine Article